53 related articles for article (PubMed ID: 1861867)
1. Altered post-translational processing of p21ras oncoprotein in a transformation-suppressed cell line.
Huang S; Axelrod DE
Oncogene; 1991 Jul; 6(7):1211-8. PubMed ID: 1861867
[TBL] [Abstract][Full Text] [Related]
2. Reversion of a human tumour cell line containing oncogenic p21ras is associated with a defect in the post-translational processing of the ras protein.
Tilbrook PA; Paterson HF; Marshall CJ
Oncogene; 1995 Feb; 10(4):805-9. PubMed ID: 7862461
[TBL] [Abstract][Full Text] [Related]
3. Role of chromosome loss in ras/myc-induced Syrian hamster tumors.
Oshimura M; Koi M; Ozawa N; Sugawara O; Lamb PW; Barrett JC
Cancer Res; 1988 Mar; 48(6):1623-32. PubMed ID: 2449958
[TBL] [Abstract][Full Text] [Related]
4. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
Ghosh PM; Ghosh-Choudhury N; Moyer ML; Mott GE; Thomas CA; Foster BA; Greenberg NM; Kreisberg JI
Oncogene; 1999 Jul; 18(28):4120-30. PubMed ID: 10435593
[TBL] [Abstract][Full Text] [Related]
5. Isolation of a new class of 'flat' revertants from ras-transformed NIH3T3 cells using cis-4-hydroxy-L-proline.
Yanagihara K; Ciardiello F; Talbot N; McGeady ML; Cooper H; Benade L; Salomon DS; Bassin RH
Oncogene; 1990 Aug; 5(8):1179-86. PubMed ID: 2202950
[TBL] [Abstract][Full Text] [Related]
6. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
[TBL] [Abstract][Full Text] [Related]
7. G-protein-mediated signaling in cholesterol-enriched arterial smooth muscle cells. 1. Reduced membrane-associated G-protein content due to diminished isoprenylation of G-gamma subunits and p21ras.
Pomerantz KB; Lander HM; Summers B; Robishaw JD; Balcueva E; Hajjar DP
Biochemistry; 1997 Aug; 36(31):9523-31. PubMed ID: 9235998
[TBL] [Abstract][Full Text] [Related]
8. Transformation-resistant mos revertant is unable to activate MAP kinase kinase in response to v-mos or v-raf.
Topol LZ; Marx M; Calothy G; Blair DG
Cell Growth Differ; 1995 Jan; 6(1):27-38. PubMed ID: 7718484
[TBL] [Abstract][Full Text] [Related]
9. Geranylgeranyl as well as farnesyl moiety is transferred to Ras p21 overproduced in adrenocortical cells transformed by c-Ha-rasEJ oncogene.
Osman H; Mazet JL; Maume G; Maume BF
Biochem Biophys Res Commun; 1997 Feb; 231(3):789-92. PubMed ID: 9070894
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Ras-induced oncogenic transformation of NIH-3T3 cells using differential-display 2-DE proteomics.
Ji H; Moritz RL; Kim YS; Zhu HJ; Simpson RJ
Electrophoresis; 2007 Jun; 28(12):1997-2008. PubMed ID: 17526045
[TBL] [Abstract][Full Text] [Related]
11. Complex formation between the p21ras GTPase-activating protein and phosphoproteins p62 and p190 is independent of p21ras signalling.
Pronk GJ; de Vries-Smits AM; Ellis C; Bos JL
Oncogene; 1993 Oct; 8(10):2773-80. PubMed ID: 8378086
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cytokinesis and akt phosphorylation by chaetoglobosin K in ras-transformed epithelial cells.
Matesic DF; Villio KN; Folse SL; Garcia EL; Cutler SJ; Cutler HG
Cancer Chemother Pharmacol; 2006 Jun; 57(6):741-54. PubMed ID: 16254733
[TBL] [Abstract][Full Text] [Related]
13. Characterization of p21Ras-mediated apoptosis induced by protein kinase C inhibition and application to human tumor cell lines.
Liou JS; Chen JS; Faller DV
J Cell Physiol; 2004 Feb; 198(2):277-94. PubMed ID: 14603530
[TBL] [Abstract][Full Text] [Related]
14. Suppression of the metastatic phenotype of a mouse skin carcinoma cell line independent of E-cadherin expression and correlated with reduced Ha-ras oncogene products.
Caulín C; López-Barcons L; Gonzáles-Garrigues M; Navarro P; Lozano E; Rodrigo I; Gamallo C; Cano A; Fabra A; Quintanilla M
Mol Carcinog; 1996 Feb; 15(2):104-14. PubMed ID: 8599577
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of p21 proteins from various cell types by two-dimensional gel electrophoresis.
Feuerstein N; Ali IU
J Cell Biochem; 1985; 29(3):253-63. PubMed ID: 3001111
[TBL] [Abstract][Full Text] [Related]
16. [Identification of a specific protein in flat revertant cell lines derived from ras oncogene-transformed cells].
Fujita H
Hokkaido Igaku Zasshi; 1990 Mar; 65(2):210-20. PubMed ID: 2194920
[TBL] [Abstract][Full Text] [Related]
17. p21ras-mediated decrease of the retinoblastoma protein in fibroblasts occurs through growth factor-dependent mechanisms.
Kivinen L; Tiihonen E; Haapajärvi T; Laiho M
Cell Growth Differ; 1996 Dec; 7(12):1705-12. PubMed ID: 8959339
[TBL] [Abstract][Full Text] [Related]
18. Specific labeling of isoprenylated proteins: application to study inhibitors of the post-translational farnesylation and geranylgeranylation.
Danesi R; McLellan CA; Myers CE
Biochem Biophys Res Commun; 1995 Jan; 206(2):637-43. PubMed ID: 7826382
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling by DNA microarray analysis in mouse embryonic fibroblasts transformed by rasV12 mutated protein and the E1A oncogene.
Vasseur S; Malicet C; Calvo EL; Labrie C; Berthezene P; Dagorn JC; Iovanna JL
Mol Cancer; 2003 Mar; 2():19. PubMed ID: 12685932
[TBL] [Abstract][Full Text] [Related]
20. Prenoids and palmitate: lipids that control the biological activity of Ras proteins.
Kato K; Der CJ; Buss JE
Semin Cancer Biol; 1992 Aug; 3(4):179-88. PubMed ID: 1421162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
